These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 17559755

  • 41. The effect of escitalopram on sleep problems in depressed patients.
    Lader M, Andersen HF, Baekdal T.
    Hum Psychopharmacol; 2005 Jul; 20(5):349-54. PubMed ID: 15912558
    [Abstract] [Full Text] [Related]

  • 42. Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine.
    Hirschfeld RM, Vornik LA.
    J Clin Psychiatry; 2004 Jul; 65 Suppl 4():46-52. PubMed ID: 15046541
    [Abstract] [Full Text] [Related]

  • 43. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety.
    Olié JP, Tonnoir B, Ménard F, Galinowski A.
    Depress Anxiety; 2007 Jul; 24(5):318-24. PubMed ID: 17041922
    [Abstract] [Full Text] [Related]

  • 44. An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches.
    Wohlreich MM, Martinez JM, Mallinckrodt CH, Prakash A, Watkin JG, Fava M.
    J Clin Psychopharmacol; 2005 Dec; 25(6):552-60. PubMed ID: 16282837
    [Abstract] [Full Text] [Related]

  • 45. Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial.
    Chokka P, Legault M.
    Depress Anxiety; 2008 Dec; 25(12):E173-81. PubMed ID: 19006260
    [Abstract] [Full Text] [Related]

  • 46. Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram).
    Mallinckrodt CH, Prakash A, Houston JP, Swindle R, Detke MJ, Fava M.
    Neuropsychobiology; 2007 Dec; 56(2-3):73-85. PubMed ID: 18037817
    [Abstract] [Full Text] [Related]

  • 47. Baseline severity of depression predicts antidepressant drug response relative to escitalopram.
    Kilts CD, Wade AG, Andersen HF, Schlaepfer TE.
    Expert Opin Pharmacother; 2009 Apr; 10(6):927-36. PubMed ID: 19317630
    [Abstract] [Full Text] [Related]

  • 48. Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: outcomes following randomized switch to either duloxetine or escitalopram.
    Raskin J, George T, Granger RE, Hussain N, Zhao GW, Marangell LB.
    J Psychiatr Res; 2012 May; 46(5):667-74. PubMed ID: 22410206
    [Abstract] [Full Text] [Related]

  • 49. Escitalopram continuation treatment prevents relapse of depressive episodes.
    Rapaport MH, Bose A, Zheng H.
    J Clin Psychiatry; 2004 Jan; 65(1):44-9. PubMed ID: 14744167
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study.
    Romera I, Pérez V, Menchón JM, Schacht A, Papen R, Neuhauser D, Abbar M, Picard H, Gilaberte I.
    J Affect Disord; 2012 Dec 20; 143(1-3):47-55. PubMed ID: 22858211
    [Abstract] [Full Text] [Related]

  • 52. A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder.
    Armstrong EP, Malone DC, Erder MH.
    Curr Med Res Opin; 2008 Apr 20; 24(4):1115-21. PubMed ID: 18331669
    [Abstract] [Full Text] [Related]

  • 53. Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-to-head randomized trials.
    Trkulja V.
    Croat Med J; 2010 Feb 20; 51(1):61-73. PubMed ID: 20162747
    [Abstract] [Full Text] [Related]

  • 54. Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder.
    Schmitt L, Tonnoir B, Arbus C.
    Neuropsychobiology; 2006 Feb 20; 54(4):201-7. PubMed ID: 17337913
    [Abstract] [Full Text] [Related]

  • 55. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Richards C, McIntyre RS, Weisler R, Sambunaris A, Brawman-Mintzer O, Gao J, Geibel B, Dauphin M, Madhoo M.
    J Affect Disord; 2016 Dec 20; 206():151-160. PubMed ID: 27474961
    [Abstract] [Full Text] [Related]

  • 56. Trial of Electrical Direct-Current Therapy versus Escitalopram for Depression.
    Brunoni AR, Moffa AH, Sampaio-Junior B, Borrione L, Moreno ML, Fernandes RA, Veronezi BP, Nogueira BS, Aparicio LVM, Razza LB, Chamorro R, Tort LC, Fraguas R, Lotufo PA, Gattaz WF, Fregni F, Benseñor IM, ELECT-TDCS Investigators.
    N Engl J Med; 2017 Jun 29; 376(26):2523-2533. PubMed ID: 28657871
    [Abstract] [Full Text] [Related]

  • 57. Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 Report.
    Kennedy SH, Lam RW, Rotzinger S, Milev RV, Blier P, Downar J, Evans KR, Farzan F, Foster JA, Frey BN, Giacobbe P, Hall GB, Harkness KL, Hassel S, Ismail Z, Leri F, McInerney S, MacQueen GM, Minuzzi L, Müller DJ, Parikh SV, Placenza FM, Quilty LC, Ravindran AV, Sassi RB, Soares CN, Strother SC, Turecki G, Vaccarino AL, Vila-Rodriguez F, Yu J, Uher R, CAN-BIND Investigator TeamMembers of the CAN-BIND Investigator Team are listed at www.canbind.ca/our-team/...
    J Clin Psychiatry; 2019 Feb 05; 80(2):. PubMed ID: 30840787
    [Abstract] [Full Text] [Related]

  • 58. Trial of Psilocybin versus Escitalopram for Depression.
    Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ.
    N Engl J Med; 2021 Apr 15; 384(15):1402-1411. PubMed ID: 33852780
    [Abstract] [Full Text] [Related]

  • 59. Efficacy and safety of escitalopram in treatment of severe depression in Chinese population.
    Si T, Wang G, Yang F, Fang Y, Fang M, Li J, Dong J, Shen X, Zhuo J, Rui Q, Wang J, Cuili H.
    Metab Brain Dis; 2017 Jun 15; 32(3):891-901. PubMed ID: 28299626
    [Abstract] [Full Text] [Related]

  • 60. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.
    Brown ES, Howard C, Khan DA, Carmody TJ.
    Psychosomatics; 2012 Jun 15; 53(1):75-80. PubMed ID: 22221724
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.